Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2000

01-04-2000 | Review

Association of MHC and rheumatoid arthritis: Regulatory role of HLA class II molecules in animal models of RA - studies on transgenic/knockout mice

Authors: Veena Taneja, Chella S David

Published in: Arthritis Research & Therapy | Issue 3/2000

Login to get access

Abstract

Human leucocyte antigen (HLA) class II molecules have been shown to be associated with predisposition to rheumatoid arthritis (RA). We generated HLA-DR and DQ transgenic mice that lacked endogenous class II molecules to study the interaction between the DR and DQ molecules and define the immunologic mechanisms in rheumatoid arthritis. Using collagen-induced arthritis (CIA) as an experimental model for inflammatory polyarthritis, we show that both DQ and DR are involved in predisposition or resistance to arthritis. Our studies suggest that polymorphism in DQB1 genes may determine predisposition to RA while the DRB1 polymorphism may dictate severity/protection of the disease. These mice provide powerful tools to develop immunotherapeutic protocols.
Literature
1.
go back to reference Hammer J, Gallazzi F, Bono E: Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med. 1995, 181: 1847-1855. 10.1084/jem.181.5.1847.PubMedCrossRef Hammer J, Gallazzi F, Bono E: Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med. 1995, 181: 1847-1855. 10.1084/jem.181.5.1847.PubMedCrossRef
2.
go back to reference Zanelli E, Gonzalez MA, David CS: Could HLA-DRB1 be the protective locus in rheumatoid arthritis. Immunol Today. 1995, 16: 274-278. 10.1016/0167-5699(95)80181-2.PubMedCrossRef Zanelli E, Gonzalez MA, David CS: Could HLA-DRB1 be the protective locus in rheumatoid arthritis. Immunol Today. 1995, 16: 274-278. 10.1016/0167-5699(95)80181-2.PubMedCrossRef
3.
go back to reference Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen induced arthritis in mice: 1. Major histocompatibility complex (I-region) linkage and antibody correlates. J Exp Med. 1981, 154: 688-700. 10.1084/jem.154.3.688.PubMedCrossRef Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen induced arthritis in mice: 1. Major histocompatibility complex (I-region) linkage and antibody correlates. J Exp Med. 1981, 154: 688-700. 10.1084/jem.154.3.688.PubMedCrossRef
4.
go back to reference Taneja V, David CS: HLA class II transgenic mice as models of human disease. Immunol Rev. 1999, 169: 67-79. 10.1111/j.1600-065X.1999.tb01307.x.PubMedCrossRef Taneja V, David CS: HLA class II transgenic mice as models of human disease. Immunol Rev. 1999, 169: 67-79. 10.1111/j.1600-065X.1999.tb01307.x.PubMedCrossRef
5.
go back to reference Yeung RSM, Penninger JM, Kundig TM: Human CD4-major histocompatibility complex class II (DQW6) transgenic mice in an endogenous CD4/CD8-deficient background: reconstitution of phenotype and human-restricted function. J Exp Med. 1994, 180: 1911-1920. 10.1084/jem.180.5.1911.PubMedCrossRef Yeung RSM, Penninger JM, Kundig TM: Human CD4-major histocompatibility complex class II (DQW6) transgenic mice in an endogenous CD4/CD8-deficient background: reconstitution of phenotype and human-restricted function. J Exp Med. 1994, 180: 1911-1920. 10.1084/jem.180.5.1911.PubMedCrossRef
6.
go back to reference Gosgrove D, Gray D, Dierich A: Mice lacking MHC Class II molecules. Cell. 1991, 66: 1051-1066. 10.1016/0092-8674(91)90448-8.CrossRef Gosgrove D, Gray D, Dierich A: Mice lacking MHC Class II molecules. Cell. 1991, 66: 1051-1066. 10.1016/0092-8674(91)90448-8.CrossRef
7.
go back to reference Nabozny GH, Baisch JM, Cheng S: HLA-DQ8 transgenic mice are highly susceptible to collagen induced arthritis: A novel model for human polyarthritis. J Exp Med. 1996, 183: 27-37. 10.1084/jem.183.1.27.PubMedCrossRef Nabozny GH, Baisch JM, Cheng S: HLA-DQ8 transgenic mice are highly susceptible to collagen induced arthritis: A novel model for human polyarthritis. J Exp Med. 1996, 183: 27-37. 10.1084/jem.183.1.27.PubMedCrossRef
8.
go back to reference Zanelli E, Krco CJ, David CS: Critical residues on HLA-DRB1*0402 HV3 peptide for HLA-DQ8-restricted immunogenicity. J Immunol. 1997, 158: 3545-3551.PubMed Zanelli E, Krco CJ, David CS: Critical residues on HLA-DRB1*0402 HV3 peptide for HLA-DQ8-restricted immunogenicity. J Immunol. 1997, 158: 3545-3551.PubMed
9.
go back to reference Taneja V, Griffiths MM, Luthra H, David CS: Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Int Immunol. 1998, 10: 1449-1457. 10.1093/intimm/10.10.1449.PubMedCrossRef Taneja V, Griffiths MM, Luthra H, David CS: Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Int Immunol. 1998, 10: 1449-1457. 10.1093/intimm/10.10.1449.PubMedCrossRef
10.
go back to reference Rosloniec EF, Brand DD, Myers LK: Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol. 1998, 160: 2573-2578.PubMed Rosloniec EF, Brand DD, Myers LK: Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol. 1998, 160: 2573-2578.PubMed
11.
go back to reference Pan S, Taneja V, Griffiths MM, Luthra H, David CS: Complementation between HLA-DR4 (DRB1*0401) and specific H2-A molecule in transgenic mice leads to collagen-induced arthritis. Hum Immunol. 1999, 60: 816-825. 10.1016/S0198-8859(99)00070-1.PubMedCrossRef Pan S, Taneja V, Griffiths MM, Luthra H, David CS: Complementation between HLA-DR4 (DRB1*0401) and specific H2-A molecule in transgenic mice leads to collagen-induced arthritis. Hum Immunol. 1999, 60: 816-825. 10.1016/S0198-8859(99)00070-1.PubMedCrossRef
12.
go back to reference Krco CJ, Watanabe S, Harders J: Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice. J Immunol. 1999, 163: 1661-1665.PubMed Krco CJ, Watanabe S, Harders J: Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice. J Immunol. 1999, 163: 1661-1665.PubMed
13.
go back to reference Hjelmstrom P, DeWeese-Scott C, Penzotti JE, Lybrand TP, Sanjeevi CB: Structural differences between HLA-DQ molecules associated with myasthenia gravis characterized by molecular modeling. J Neuroimmunol. 1998, 85: 102-105. 10.1016/S0165-5728(97)00266-X.PubMedCrossRef Hjelmstrom P, DeWeese-Scott C, Penzotti JE, Lybrand TP, Sanjeevi CB: Structural differences between HLA-DQ molecules associated with myasthenia gravis characterized by molecular modeling. J Neuroimmunol. 1998, 85: 102-105. 10.1016/S0165-5728(97)00266-X.PubMedCrossRef
14.
go back to reference Kjellen P, Brunsberg U, Broddefalk J: The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. Eur J Immunol. 1998, 28: 755-767. 10.1002/(SICI)1521-4141(199802)28:02<755::AID-IMMU755>3.0.CO;2-2.PubMedCrossRef Kjellen P, Brunsberg U, Broddefalk J: The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. Eur J Immunol. 1998, 28: 755-767. 10.1002/(SICI)1521-4141(199802)28:02<755::AID-IMMU755>3.0.CO;2-2.PubMedCrossRef
15.
go back to reference Matsushita S, Nishi T, Oiso M: HLA-DQ binding motifs. Comparative analysis of type II collagen-derived peptides to DR and DQ molecules of rheumatoid arthritis-susceptible and non-susceptible haplotypes. Int Immunol. 1996, 8: 757-764.PubMedCrossRef Matsushita S, Nishi T, Oiso M: HLA-DQ binding motifs. Comparative analysis of type II collagen-derived peptides to DR and DQ molecules of rheumatoid arthritis-susceptible and non-susceptible haplotypes. Int Immunol. 1996, 8: 757-764.PubMedCrossRef
Metadata
Title
Association of MHC and rheumatoid arthritis: Regulatory role of HLA class II molecules in animal models of RA - studies on transgenic/knockout mice
Authors
Veena Taneja
Chella S David
Publication date
01-04-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar88

Other articles of this Issue 3/2000

Arthritis Research & Therapy 3/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine